Coherus BioSciences, Inc. announced the appointment of former investment banker and renowned biotech strategist Charlie Newton to its Board of Directors. Mr. Newton will also serve on the Audit Committee of the Board of Directors. Mr. Newton is the Chief Financial Officer of Lyell Immunopharma, a NASDAQ-listed biotechnology company.

Prior to joining Lyell, he served as Managing Director & Co-Head of Healthcare Investment Banking in the Americas at BofA Securities, Managing Director & Co-Head of Healthcare Investment Banking in the Americas at Credit Suisse, and Managing Director & Head of Western Region Healthcare Investment Banking at Morgan Stanley.